Status:
COMPLETED
Effects of Co-treatment on Endometrial abv3-integrin Expressions in Women With Recurrent Implantation Failure
Lead Sponsor:
Universiti Kebangsaan Malaysia Medical Centre
Conditions:
Miscarriage, Recurrent
Eligibility:
FEMALE
18-40 years
Phase:
NA
Brief Summary
To compare the abv3-integrin expression in endometrium tissue among RIF women between the GnRH analogue with Aromatase Inhibitor (Group A) , GnRH analogue with progesterone (Group B) and GnRH analogue...
Detailed Description
i. To determine the abv3-integrin expression isolated from endometrium tissue from women with RIF prior to medical therapy. ii. To determine the abv3-integrin expression isolated from endometrium tis...
Eligibility Criteria
Inclusion
- Women of 18 to 40 years of age
- No significant pre-existing major medical.
- Diagnosed as recurrent implantation failure - at least two or more failure of achieving pregnancy following embryo transfer (ET) despite the optimum endometrial thickness and good quality of embryo (unexplained).
- Regular menstrual cycle atleast 3 months prior to treatment
- Not taking any hormonal treatment for atlest 3months prior to recruitment
- Agreed to participate
Exclusion
- Concurrent significant pre-existing major medical conditions such as uncontrolled diabetes, active systemic lupus erythematosus (SLE) or Anti Phospholipid Syndrome (APS) that will interfere with implantation.
- Poor quality of embryo
- Suboptimal endometrial thickness(\<8mm) during the embryo transfer (ET).
- On hormonal therapy prior to recruitment.
- Not agreed to participate
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 30 2022
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT05437471
Start Date
January 1 2020
End Date
May 30 2022
Last Update
June 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UniversitiKMMC
Kuala Lumpur, Malaysia, 56000